No profile data available.
Stevanato Group S.p.A. (STVN) is a healthcare company in the additional medication administration equipment industry, based in Piombino Dese, Italy, with about 6,010 full-time employees.
It reported revenue of 1.19 billion EUR for fiscal year 2025, up 7.4% from fiscal year 2024, and net income of 139.84 million EUR. Its largest business segment, Biopharmaceutical and Diagnostic Solutions, brought in 79% of segment revenue in fiscal year 2025; EMEA was the largest region with 58%. Its market capitalization was $5.30 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Stevanato Group S.p.A. reported 1.19 billion EUR in revenue for fiscal year 2025, up 7.4% from 1.10 billion EUR in fiscal year 2024.
Biopharmaceutical and Diagnostic Solutions, with 1.04 billion EUR or 79% of segment revenue in fiscal year 2025. Next: Engineering (21%).
EMEA: 58% of revenue by region in fiscal year 2025, followed by North America (31%).
$5.30 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional medication administration equipment) include West Pharmaceutical Services, Inc. (WST), Embecta Corp. (EMBC), Retractable Technologies, Inc. (RVP), Biora Therapeutics, Inc. (BIOR).